GE HealthCare二季度订单强劲但全年指引维持不变，PCS业务仍承压

Earnings Call Insights: GE HealthCare (GEHC) Q2 2026
Management view
- “We were pleased with our strong performance in the second quarter” and “Orders increased 11% with strong backlog, which grew $2.6 billion year-over-year and book-to-bill of 1.15x, all of which were at record levels,” said President, CEO & Director Peter Arduini.
- “Patient Care Solutions performance remained challenged,” and management said it is “actioning improvement initiatives via our business system Heartbeat with a focus on increasing shipment velocity and backlog conversion of our monitoring and anesthesia product lines to deliver PCS revenue and margin improvement in the second half,” said President, CEO & Director Arduini.
- “A comprehensive review of the strategic options is underway to determine the best path to maximize long-term growth and value, including continued ownership, a sale and other value-enhancing transactions,” said President, CEO & Director Arduini, describing potential paths for Patient Care Solutions.
- “We delivered revenue of $5.3 billion, representing 3.5% organic growth year-over-year,” and “Organic orders growth was robust, up 11.1% year-over-year, the highest since our spin,” said VP & CFO James Saccaro.
- “Jay has helped build a strong financial organization,” and “I have full confidence in George Newcomb, our incoming interim CFO,” said President, CEO & Director Arduini.
Outlook
- “We’re maintaining full year guidance,” said President, CEO & Director Arduini: “3% to 4% organic sales growth,” “10 to 40 basis points adjusted EBIT margin expansion that gets us to a range of 15.4% to 15.7%,” and “adjusted EPS guidance in the range of $4.80 to $5.”
- Management pointed to second-half drivers including “PCS stabilization,” “Flyrcado growth,” and order conversion, with VP & CFO Saccaro saying, “our secured rate on equipment, we’re about over 80%, nearly 85% secured entering the quarter.”
- On why guidance was not raised, President, CEO & Director Arduini said, “we recognized $0.04 of adjusted EPS related to the ’26 tariffs within the P&L,” and “we just thought it made sense to kind of stay where we’re at.”
Financial results
- “Book-to-bill was 1.15x,” and “we exited the quarter with a record backlog of $23.9 billion,” said VP & CFO Saccaro.
- “Adjusted EBIT of $750 million included $23 million in recognized refunds from IEEPA tariffs incurred in the first quarter of 2026,” and “Adjusted EBIT margin of 14.2% was down 40 basis points year-over-year,” said VP & CFO Saccaro.
- “We delivered adjusted EPS of $1.13 in the quarter,” and “our free cash flow was $68 million in the quarter, which includes tariff refunds of $107 million,” said VP & CFO Saccaro.
- Segment highlights included “Advanced Imaging Solutions… Organic revenue grew 5% year-over-year” and “EBIT margin increased 90 basis points year-over-year,” plus “Pharmaceutical Diagnostics… organic revenue growth of 14.6%” with “EBIT margin of 29.6%,” said VP & CFO Saccaro.
- The key downside remained Patient Care Solutions: “Organic revenue declined 13.5% and segment EBIT was negative,” said VP & CFO Saccaro.
Q&A
- Larry Biegelsen, Wells Fargo: asked if Q2 order strength had “anything one-time” and about U.S. capital equipment demand; President, CEO & Director Arduini replied, “There really weren’t any particular one-timers,” adding it was “broad-based” with “about 6 enterprise accounts” contributing.
- Larry Biegelsen, Wells Fargo: asked about second-half acceleration; VP & CFO Saccaro cited “over 7% order growth” on a “2-year stack,” “nearly 85% secured entering the quarter,” and said margin should improve “over 300 basis points… from the first half to the second half.”
- Vijay Kumar, Evercore ISI: asked about PDx strength and Flyrcado; President, CEO & Director Arduini said, “we delivered 545 doses for the week ending July 24,” and “The longer-term opportunity of $0.5 billion annually by 2028 is fully intact.”
- Vijay Kumar, Evercore ISI: asked about CFO transition; VP & CFO Saccaro said it was “a very unique opportunity… to expand my role beyond finance,” and President, CEO & Director Arduini said, “we just kicked it off” and “We’re going to move quite quickly.”
- Travis Steed, BofA: asked about inflation; VP & CFO Saccaro said, “In the second quarter, inflation was about 120 basis point headwind,” and “the $250 million assumption… is still the appropriate amount.”
- Travis Steed, BofA: asked about PCS stabilization and the strategic review; President, CEO & Director Arduini said, “we had operational fulfillment challenges,” expects “improvement… within the second half,” and said the review spans “multiple alternatives.”
- Joanne Wuensch, Citi: asked about China; President, CEO & Director Arduini said, “we were pleased with our China performance in Q2,” but “it’s prudent to continue to assume kind of a year-over-year decline in 2026.”
- [Henry] on for Robbie, JPMorgan: asked about generic Omnipaque and EPS guidance; VP & CFO Saccaro said, “we haven’t seen any impact at this point at all,” and President, CEO & Director Arduini said, “we have the appropriate cushion here to meet and potentially exceed.”
Sentiment analysis
- Analysts were slightly negative to pressing on sustainability and downside risks, including “concerns around capital equipment demand,” “why… not to raise the EPS guidance,” and whether the CFO change was “abrupt,” as asked by Wells Fargo, JPMorgan, and Evercore.
- Management was slightly positive in prepared remarks and more defensive in Q&A on guidance and offsets, including “I’m not going to get into hypotheticals,” and “we just thought it made sense… to kind of stay where we’re at,” said President, CEO & Director Arduini.
- Versus Q1, the tone shifted from inflation-driven caution (Q1: “reducing our profit and free cash flow guidance for 2026,” said President, CEO & Director Arduini) to steadier execution emphasis in Q2 (“we’re maintaining full year guidance,” said President, CEO & Director Arduini).
Quarter-over-quarter comparison
- Q2 emphasized record demand signals, with “Organic orders growth… up 11.1%… the highest since our spin,” said VP & CFO Saccaro, versus Q1’s “Orders grew 1.1%,” said VP & CFO Saccaro.
- Q2 introduced a new strategic action on PCS: “a comprehensive review of the strategic options is underway,” said President, CEO & Director Arduini; Q1 framed PCS as operational improvement, including “focused on improving backlog conversion… and optimizing segment cost structure,” said VP & CFO Saccaro.
- Q2 highlighted leadership change: “George Newcomb, our incoming interim CFO,” said President, CEO & Director Arduini; Q1 did not discuss a CFO transition.
Risks and concerns
- Management cited operational and margin risk from “operational fulfillment challenges” in PCS and said mitigation is “daily focus and weekly execution plans,” said VP & CFO Saccaro.
- Management highlighted inflation volatility in “memory chips, oil and freight,” while saying pricing and cost actions should “carry us through into the second half,” said VP & CFO Saccaro.
- Competitive risk in contrast media was discussed with VP & CFO Saccaro noting, “we never underestimate competition,” while also stating, “we haven’t seen an impact to date.”
Final takeaway
Management described Q2 as a demand-driven quarter with record backlog and order momentum, while keeping full-year guidance unchanged and pointing to second-half execution as the main swing factor. The most consequential new strategic development was the formal review of Patient Care Solutions alternatives alongside efforts to stabilize supply and restore volume-driven profitability, with a CFO transition underway to interim CFO George Newcomb as the company continues its AI-enabled product cycle and cost/price actions into the back half.
Read the full Earnings Call Transcript